Search

Your search keyword '"Castagna, Luca"' showing total 12 results
Start Over Author "Castagna, Luca" Journal leukemia & lymphoma
12 results on '"Castagna, Luca"'

1. The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

Author

Wanquet, Anne, primary, Crocchiolo, Roberto, additional, Furst, Sabine, additional, Granata, Angela, additional, Faucher, Catherine, additional, Devillier, Raynier, additional, Harbi, Samia, additional, Lemarie, Claude, additional, Calmels, Boris, additional, Vey, Norbert, additional, Weiller, Pierre Jean, additional, Chabannon, Christian, additional, Castagna, Luca, additional, Blaise, Didier, additional, and El-Cheikh, Jean, additional

Published
2016
Full Text
View/download PDF

2. The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

Author

Wanquet, Anne, Crocchiolo, Roberto, Furst, Sabine, Granata, Angela, Faucher, Catherine, Devillier, Raynier, Harbi, Samia, Lemarie, Claude, Calmels, Boris, Vey, Norbert, Weiller, Pierre Jean, Chabannon, Christian, Castagna, Luca, Blaise, Didier, and El-Cheikh, Jean

Subjects
STEM cell transplantation, HOMOGRAFTS, BUSULFAN, PHYSICAL training & conditioning, TOXICITY testing, DRUG efficacy
Abstract

The optimal intensity of myeloablation associated with a reduced-toxicity conditioning (RTC) regimen in order to decrease the relapse rate without increasing non-relapse mortality (NRM), is not well established yet. This retrospective analysis was done on 30 patients with hematological malignancies. The aim was to assess the safety of a RTC regimen based on the busulfan at a dose of 100 mg/m2/d intravenously for 4 d, fludarabine at a dose of 30 mg/m2/d for 5 d, and anti-thymoglobulins at a dose of 2.5 mg/kg/d for 2 d. The cumulative incidences of grade 2–4 acute graft-versus-host disease (GVHD) and all grades chronic GVHD were 37% and 42%, respectively. Median 1-year overall survival and disease-free survival were 66% and 50%, respectively. At 1 year, the cumulative incidence of relapse/disease progression was 33%. NRM was 3% and 17% at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

3. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine–busulfan–antithymocyte globulin conditioning regimen

Author

Saillard, Colombe, primary, Crocchiolo, Roberto, additional, Furst, Sabine, additional, El-Cheikh, Jean, additional, Castagna, Luca, additional, Signori, Alessio, additional, Oudin, Claire, additional, Faucher, Catherine, additional, Lemarie, Claude, additional, Chabannon, Christian, additional, Granata, Angela, additional, and Blaise, Didier, additional

Published
2014
Full Text
View/download PDF

4. Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma

Author

Crocchiolo, Roberto, primary, Chabannon, Christian, additional, El-Cheikh, Jean, additional, Esterni, Benjamin, additional, Lemarié, Claude, additional, Fürst, Sabine, additional, Castagna, Luca, additional, Bouabdallah, Reda, additional, Ladaique, Patrick, additional, Coso, Diane, additional, Schiano, Jean Marc, additional, Stoppa, Anne Marie, additional, Rey, Jerome, additional, Ivanov, Vadim, additional, Aurran, Therese, additional, Faucher, Catherine, additional, Blaise, Didier, additional, and Calmels, Boris, additional

Published
2012
Full Text
View/download PDF

5. Successful treatment of post-transplant Epstein–Barr virus-related meningoencephalitis by intravenous rituximab monotherapy

Author

Crocchiolo, Roberto, primary, Ciccolini, Joseph, additional, El-Cheikh, Jean, additional, Fürst, Sabine, additional, Castagna, Luca, additional, Granata, Angela, additional, Oudin, Claire, additional, Harbi, Samia, additional, Devillier, Raynier, additional, Legall, Stevan, additional, Ternant, David, additional, Paintaud, Gilles, additional, Lacarelle, Bruno, additional, and Blaise, Didier, additional

Published
2012
Full Text
View/download PDF

6. Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?

Author

El-Cheikh, Jean, primary, Crocchiolo, Roberto, additional, Boher, Jean-Marie, additional, Fürst, Sabine, additional, Stoppa, Anne Marie, additional, Faucher, Catherine, additional, Castagna, Luca, additional, Granata, Angela, additional, Oudin, Claire, additional, de Colella, Jean-Marc Schiano, additional, Coso, Diane, additional, Bouabdallah, Reda, additional, Mohty, Mohamad, additional, and Blaise, Didier, additional

Published
2012
Full Text
View/download PDF

10. Letter to the Editor

Author

Magagnoli, Massimo, primary, Balzarotti, Monica, additional, Castagna, Luca, additional, Rahal, Daoud, additional, Siracusano, Licia, additional, Nozza, Andrea, additional, and Santoro, Armando, additional

Published
2003
Full Text
View/download PDF

12. Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma.

Author

Crocchiolo, Roberto, Chabannon, Christian, El-Cheikh, Jean, Esterni, Benjamin, Lemarié, Claude, Fürst, Sabine, Castagna, Luca, Bouabdallah, Reda, Ladaique, Patrick, Coso, Diane, Schiano, Jean Marc, Stoppa, Anne Marie, Rey, Jerome, Ivanov, Vadim, Aurran, Therese, Faucher, Catherine, Blaise, Didier, and Calmels, Boris

Subjects
MULTIPLE myeloma, HEMATOPOIETIC stem cells, LYMPHOMAS, B cell lymphoma, STEM cell transplantation
Abstract

The article discusses research which investigated poor autologous mobilization incidence in multiple myeloma (MM) and lymphoma patients that received reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (alloSCT). Topics explored include the use of antithymocyte globulin conditioning in alloSCT, the classification of patients that are deemed as either good or poor mobilizers, and the adverse events recorded following alloSCT.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results